Search Results | Blood | American Society of Hematology

1-20 of 109

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients

Gage S. Black, Xiaomeng Huang, Yi Qiao, Szabolcs Tarapcsak, Kerry A. Rogers, Shrilekha Misra, John C. Byrd, Gabor T. Marth, Deborah M. Stephens, Jennifer A. Woyach

Blood blood.2021015132.

DOI: https://doi.org/10.1182/blood.2021015132

Published: 2022

Includes: Supplemental data

Journal Articles

Boosting BNT162b2 vaccine efficacy in CLL

Seema A. Bhat, Jennifer A. Woyach

Blood (2022) 139 (5): 639–640.

DOI: https://doi.org/10.1182/blood.2021014903

Published: 2022

Journal Articles

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V. Abruzzo, Kyle Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach

Blood (2021) 138 (23): 2372–2382.

DOI: https://doi.org/10.1182/blood.2020010536

Published: 2021

Includes: Supplemental data

Journal Articles

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Cecelia Miller, Ying Huang, Jonathan Hyak, Matthew R Avenarius, Amy S. Ruppert, John C. Byrd, Seema A Bhat, Michael R Grever, Adam S Kittai, Kerry Rogers, Nyla A. Heerema, Lynne V. Abruzzo, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 1563.

DOI: https://doi.org/10.1182/blood-2021-150722

Published: 2021

Journal Articles

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Javier Pinilla Ibarz, Meixiao Long, John Lister, Jennifer A. Woyach, Friedrich Graf Finckenstein, Madan Jagasia, Selda Samakoglu, Bhagyashree Yadav, Huiling Li, John C. Byrd

Blood (2021) 138 (Supplement 1): 3846.

DOI: https://doi.org/10.1182/blood-2021-145775

Published: 2021

Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd

Blood (2021) 138 (Supplement 1): 3728.

DOI: https://doi.org/10.1182/blood-2021-151471

Published: 2021

Journal Articles

Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy

Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A Bhat, John C. Byrd, Kerry Rogers, Jennifer A. Woyach, Adam S Kittai

Blood (2021) 138 (Supplement 1): 3729.

DOI: https://doi.org/10.1182/blood-2021-148719

Published: 2021

Journal Articles

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Adam S Kittai, Ying Huang, Ashleigh Keiter, Kyle A Beckwith, Daniel Goldstein, Seema A Bhat, David A. Bond, John C. Byrd, Michael R Grever, Kerry A Rogers, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 3731.

DOI: https://doi.org/10.1182/blood-2021-144518

Published: 2021

Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Blood (2021) 138 (Supplement 1): 639.

DOI: https://doi.org/10.1182/blood-2021-153146

Published: 2021

Journal Articles

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Anthony R. Mato, William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu, Safi Shahda, Ching Ching Leow, Constantine S. Tam, Jennifer A. Woyach, Toby A. Eyre

Blood (2021) 138 (Supplement 1): 3742.

DOI: https://doi.org/10.1182/blood-2021-145936

Published: 2021

Journal Articles

Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax

Janani Ravikrishnan, Elizabeth M. Muhowski, Tzung-Huei Lai, Shrilekha Misra, Daisy Diaz Rohena, Felai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Yue Shen, John C. Byrd, Deepa Sampath, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 679.

DOI: https://doi.org/10.1182/blood-2021-151852

Published: 2021

Journal Articles

Characterization of Residual CLL Following Long-Term Bruton Tyrosine Kinase Inhibitor Therapy

Shanmugapriya Thangavadivel, Alexander Pan, Xi Chen, Chen Song, Claire Snyder, Kerry Rogers, Seema A Bhat, Adam S Kittai, Bradley W Blaser, James S. Blachly, Pearlly S. Yan, John C. Byrd, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 2620.

DOI: https://doi.org/10.1182/blood-2021-154309

Published: 2021

Journal Articles

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Inhye E. Ahn, Amy S. Ruppert, Adrian Wiestner, James S. Blachly, John C. Byrd, Richard M. Stone, Sumithra J Mandrekar, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 2642.

DOI: https://doi.org/10.1182/blood-2021-153822

Published: 2021

Journal Articles

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Daisy Diaz Rohena, Janani Ravikrishnan, Chaomei Liu, Guangrong Zheng, Daohong Zhou, Peiyi Zhang, William G. Wierda, Nitin Jain, Jennifer A. Woyach, Deepa Sampath

Blood (2021) 138 (Supplement 1): 2252.

DOI: https://doi.org/10.1182/blood-2021-151982

Published: 2021

Journal Articles

Evaluating the Carg Chemotherapy Toxicity Calculator Among Older Adults Newly Diagnosed with Hematologic Malignancy

Ashley E. Rosko, Sarah A Wall, Ying Huang, Alice S. Mims, Jennifer A. Woyach, Erin Stevens, Allesia Funderburg, Kaitlyn Dvorak, Christin Burd, Carolyn Presley, Michelle Naughton

Blood (2021) 138 (Supplement 1): 1931.

DOI: https://doi.org/10.1182/blood-2021-153850

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 381.

DOI: https://doi.org/10.1182/blood-2021-149138

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 391.

DOI: https://doi.org/10.1182/blood-2021-147599

Published: 2021

Journal Articles

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Wayne Wang, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

Blood (2021) 138 (Supplement 1): 392.

DOI: https://doi.org/10.1182/blood-2021-148672

Published: 2021

Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda

Blood (2021) 137 (24): 3327–3338.

DOI: https://doi.org/10.1182/blood.2020009617

Published: 2021

Includes: Supplemental data

Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD

Blood (2020) 136 (Supplement 1): 2–3.

DOI: https://doi.org/10.1182/blood-2020-136714

Published: 2020

2 3 4 5

NARROW

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients

Boosting BNT162b2 vaccine efficacy in CLL

The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib

Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Evaluation of the Incidence and Risk Factors Associated with Bleeding Events in Patients Receiving Acalabrutinib Therapy

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax

Characterization of Residual CLL Following Long-Term Bruton Tyrosine Kinase Inhibitor Therapy

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Evaluating the Carg Chemotherapy Toxicity Calculator Among Older Adults Newly Diagnosed with Hematologic Malignancy

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only